PPT-New Drugs in Development

New Drugs in Development Are We Ready for LongActing ART Melanie A Thompson MD AIDS Research Consortium of Atlanta Follow me on Twitter drmt Financial Relationships With Commercial Entities Dr Thompsons institution has received grants for research from BristolMyers Squibb CytoDyn Inc Frontier Biotechnologies Gilead Sciences Inc GlaxoSmithKline. In the last two years two new drugs have been approved for the treatment of MDR TB under specific conditions bedaquiline and delamanid There are currently 15 vaccine candidates in clinical trials US billion per year is needed for a full response to “. EMERGING THERAPIES FOR RARE DISEASES. ”. Emil D. Kakkis, M.D., Ph.D. .. President and . Founder. CENTER FOR ORPHAN DISEASE RESEARCH . AND . THERAPY SYMPOSIUM. FRIDAY . MAY 2, 2014. A new proposal to foster greater orphan drug development. 1. The OPEN ACT. O. rphan. . P. roduct. . E. xtensions. . N. ow. A. ccelerating. . C. ures. . &. . T. reatments. www.CureTheProcess.org. 500,000 cases annually of MDR TB. Second line treatment toxic and weak. 15% of TB is HIV-related. Drug-drug interactions problematic. 15% of TB is in children. Formulations inadequate, dosages poorly understood. drugs ( Table 2 ). 12 beyond preclinical development have been discussed in this chapter. Repurposed Existing Antituberculosis Drugs Fluoroquinolones Fluoroquinolones are deoxyribonucleic acid (DNA) Science, Technology, and Global Health. The Need for New Products. Characteristics of new technologies must reflect the following: . Most important target groups are poor people . Quality of care and injection safety is often low. Ages 11 to 18. Identity. Erikson. Identity vs. role confusion. “Who am I”. Identity Not Yet Achieved. Role confusion (Identity . diffusion. ). Don’t know, don’t care. Few commitments to goals or values. February 28, 2012. Lacy-Ann . Landell. , MD. Ryan Morgan, MD. Improving Research, Development, Access, and Safety of Pediatric Drugs and Medical Devices. Overview. Background. Barriers to the development and access of pediatric drugs and devices. D.1: Pharmaceutical products and drug action. D.2: Aspirin and Penicillin. D.1: Medicines and drugs have a variety of different effects on the functioning body. D.2: Natural products with useful medicinal properties can be chemically altered to produce more potent and safe medicines. . Dr Arif Hashmi. Objectives. a. Discuss . the principles of prescribing drugs during pregnancy, lactation and menstruation. . b. Discuss the physiological changes occurring in pregnancy that affect the pharmacodynamics and pharmacokinetics in mother. . 13/2/2018. Dr. . Athmar. . Dhahir. Habeeb. PhD in Industrial pharmacy and drug delivery. athmar1978@yahoo.com. a. th. mar.habeeb.12@ucl.ac.uk. New drug development and approval process. Current good manufacturing practices. abuse in pregnancy. Prof. Hanan Hagar. Dr. Ishfaq Bukhari. Pharmacology Unit. College of Medicine. Placental membrane is . semi-permeable.. Most drugs can cross placenta by . passive diffusion.. The movement of drugs across the placenta is limited by a single layer of cell called . Phrmacognosy. Anju. Singh. School of Pharmaceutical Sciences. CSJMU, Kanpur. Introduction of . Pharmacognosy. DEFINITION OF PHARMACOGNOSY. Pharmacognosy. . is the study of the medicinal uses of crude drugs obtained from plants and natural resources. . of Pharmacy . Practice. Dr. Haider Raheem. Tracing the origins of pharmacy. Sumerians. • The development of cuneiform writing on clay tablets during the third millennium BC included lists of drugs of animal, vegetable and mineral origin that were used in the management of diseases, and prescriptions with details of the ingredients used in their compounding.